newsfilter
← Latest News
GlobeNewswire·

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB Filsuvez® will be the first and only approved treatment for EB Patients DUBLIN, Ireland, and Boston MA, June 23, 2022, Amryt (NASDAQ:AMYT), a global, com